Company intelligence / Profile preview

Somagenetix

Zurich, Zurich, Switzerlandsomagenetix.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Somagenetix has demonstrated strong safety and efficacy for its lead candidate SGX-001 in GLP-compliant preclinical animal studies. The product has Orphan Drug Designation from both the FDA and EMA. Clinical trials are planned to start in 2026 targeting p47-CGD. The company’s novel promoter technology addresses previous limitations of viral vector-based gene therapies by ensuring specificity, long-term efficacy, and safety.

Therapeutic areas: ImmunologyNeurology
Modalities: Gene therapyLentivirus-transduced stem cell therapyEx-vivo gene therapyBiologic (by convention, as gene therapies are biologics)
Industry: Biotech

Drug pipeline

3 assets

SGX-001

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Wyss Zurich Translational Center supports preclinical development of p47-CGD program.Open to strategic partnerships with pharma & biotech companies.

Beyond the preview

Go deeper on Somagenetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Somagenetix.

Explore the full profile